| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 18,654 | 19,032 | 12:20 | |
| 18,568 | 18,850 | 12:02 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 19,320 | 606 | |||
| 19,200 | 16 | |||
| 19,156 | 39 | |||
| 19,104 | 800 | |||
| 19,100 | 1.272 | |||
| 19,096 | 400 | |||
| 19,092 | 2 | |||
| 19,090 | 403 | |||
| 18,976 | 149 | |||
| 18,974 | 631 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/via.htm [/URL] | ||||
| 49 | 18,654 | |||
| 65 | 18,652 | |||
| 2 | 18,538 | |||
| 803 | 18,534 | |||
| 800 | 18,528 | |||
| 606 | 18,498 | |||
| 300 | 18,472 | |||
| 1.272 | 18,312 | |||
| 150 | 18,000 | |||
| 800 | 17,628 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.847 | 0,891 | 4.318 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | -0,010 -0,05 % | 11 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:10 | Viatris auf der UBS Global Biopharma Conference 2026: Wachstumsstory gewinnt an Dynamik | 7 | Investing.com Deutsch | ||
| Do | Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal | 5 | Seeking Alpha | ||
| 08.11. | Viatris (NDQ:VTRS): Meet The Company Behind Viagra! But Can Yesterday's Blockbuster Still Build Tommorrow's Returns and How? | 11 | Stocks Down Under | ||
| VIATRIS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Jefferies raises Viatris stock price target to $22 on guidance lift | 17 | Investing.com | ||
| 06.11. | Jefferies hebt Kursziel für Viatris nach Prognoseanhebung auf 22 US-Dollar an | 32 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 03:58 | Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR) | GlobeNewswire (Europe) | Cosentyx (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on its decade-long... ► Artikel lesen | |
| Mo | F. Hoffmann-La Roche Ltd: FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer | GlobeNewswire (Europe) | Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial... ► Artikel lesen | |
| 08:42 | RBC stuft ROCHE HOLDINGS AG auf 'Outperform' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Roche auf "Outperform" mit einem Kursziel von 400 Franken belassen. Trung Huynh sieht die überraschend frühe Zulassung von... ► Artikel lesen | |
| 08:25 | Q3 review: an extra dose of upside; chg.: Pentixapharm enrolment and expected Q2 2027 partnering offer re-rating ... | NuWays | Pentixapharm's Q3 update reinforces the BUY case ahead of PANDA's start and potential partnering in 2027. Regulatory preparations have advanced, new oncology data strengthen the opportunity beyond primary... ► Artikel lesen | |
| 09:06 | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | Business Wire | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen |